logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
M

Minhu Chen

The First Affiliated Hospital of Sun Yat-sen University
H指数:11
被引数:921

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sustained Efficacy and Safety of Mirikizumab Through 152 Weeks in Chinese Patients with Moderately to Severely Active Crohn’s Disease: A Subpopulation Analysis of the VIVID-1 and VIVID-2 Phase 3 Trials

中国中重度活动性克罗恩病患者中mirikizumab长达152周的持续疗效与安全性：VIVID-1和VIVID-2 III期试验的亚组分析

Biodrugs
IF6.9
2026-10-280
PRE
Xiang Gao; Qian Cao; Xiaowei Liu; Baili Chen; Wenjia Liu; Wen Tang; Yufang Wang; Jie Zhong; Zhaotao Li; Xiaoyan Wang; Yi Sun; Prashant Gupta; Jiao Yu; Jiawei Xu; Minhu Chen
Characteristics and predictors of technically difficult peroral endoscopic myotomy in esophageal motility disorders: a high-volume center analysis of 676 procedures

食管动力障碍患者经口内镜下肌切开术的技术难点特征及预测因素：一项高容量中心676例手术分析

Surgical Endoscopy and Other Interventional Techniques
IF2.7
2026-02-010
PRE
Huang, Zhen-Zi; Xiao, Ying-Lian; Luo, Huang-Xin; Liu, Hao-Lin; Li, Yuan-Qi; Tian, Hong-Zhan; He, Gan-Qing; Wang, Jin-Hui; Cui, Yi; Ding, Zhen; Chen, Min-Hu; Xing, Xiang-Bin
Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cells

GCGR/GLP1R信号的协同激活通过调节上皮细胞中组蛋白H3K9乳酰化代谢来改善肠道纤维化。

ACTA PHARMACEUTICA SINICA B
IF14.6
2025-01-011
OAAI
Liu, H; Hong, YJ; Chen, H; Wang, XG; Dong, JL; Li, XQ; Shi, ZH; Zhao, Q; Zhou, LY; Wang, JX; Zeng, QL; Tang, QL; Liu, Q; Rieder, F; Chen, BL; Chen, MH; Wang, R; Zhang, Y; Mao, R; Jiang, XX
Multi-Omics Biomarkers for Predicting Efficacy of Biologic and Small-Molecule Therapies in Adults With Inflammatory Bowel Disease: A Systematic Review

用于预测炎症性肠病成人的生物和小分子疗法疗效的多组学生物标志物: 系统评价

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
IF6.7
2024-12-100
OAAI
Chen, Liru; Zhang, Chuhan; Niu, Ruixuan; Xiong, Shanshan; He, Jinshen; Wang, Yu; Zhang, Pingxin; Su, Fengyuan; Liu, Zishan; Zhou, Longyuan; Mao, Ren; Hu, Shixian; Chen, Minhu; Qiu, Yun; Feng, Rui
Early Symptomatic Improvement With Mirikizumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 VIVID-1 Study

中重度活动性克罗恩病患者中，使用Mirikizumab诱导治疗早期症状改善：来自III期VIVID-1研究的结果

AMERICAN JOURNAL OF GASTROENTEROLOGY
IF7.6
2024-10-010
PRE
Sands, BE; Chen, MH; Danese, S; Fischer, M; Hisamatsu, T; Hoque, S; Peyrin-Biroulet, L; Seibold, F; Durand, F; Lin, ZT; Lopes, M; Morris, N; Hon, E; D'Haens, GR

研究方向

暂未获取到该数据
陈百利 封面图
陈百利
H 指数:27论文数:127被引数:2,457
R
Ren Mao
H 指数:38论文数:257被引数:6,305
Y
Yun Qiu
H 指数:53论文数:260被引数:1.0万
Z
Zhirong Zeng
H 指数:26论文数:190被引数:2,042
S
Shanshan Xiong
H 指数:24论文数:89被引数:2,723
L
Longyuan Zhou
H 指数:5论文数:14被引数:128
Y
Yao He
H 指数:28论文数:146被引数:2,654
C
Caiguang Liu
H 指数:11论文数:27被引数:351
J
Jinshen He
H 指数:11论文数:27被引数:377
X
Xiang Gao
H 指数:29论文数:207被引数:3,449